Brainstorm Health: Teva CEO Interview, Amazon and Anti-Vaxxers, Philippines Vs Sanofi
Companies, agencies, institutions, etc
Teva
the New York Stock Exchange
NYSE
FDA
Time
House
Amazon
House Intelligence Committee
CNN
Sanofi
The Philippine Department of Justice
Dengvaxia
Justice Department
The Food and Drug Administration
meds’
Fortune)Insurers
Medicare
The Partnership for America’s
Health Care Future
Data Privacy Legislation
Big Tech
Anne Fisher Find
People
Kare Schultz
Adam Schiff
Jeff Bezos
Adam LashinskyWhy
Rey
Julie SweetWhy
Groups
French
Philippine
Democratic
Physical locations
No matching tags
Places
Blockchain
Locations
Teva
Israel
U.S.
Ajovy
D-CA
Philippines
Events
No matching tags
Summary
“But then I got interested because I like companies that do great products, and it turned out that Teva had this amazing portfolio of drugs that they developed on their own, in multiple sclerosis, in Parkinson’s, and other diseases.”Schultz’s mission has been to take a jackhammer to the company’s organizational structure in an effort to reorient its balance sheet, which included some $35 billion in debt fueled in part by a series of expensive acquisitions (some of which turned out be not-so-lucrative, according to Schultz). The strategy going forward will focus on debt reduction—a somewhat painful endeavor involving the elimination of 25% of Teva’s workforce—that will slash $3 billion from the firm’s spending base; a series of new branded product launches, such as the recently FDA-approved migraine treatment Ajovy; and an effort to stabilize the flagging U.S. generics business.“I came in with a clarified strategy in my head and backing from the board to actually do it,” said Schultz.
As said here by Sy Mukherjee